ClinicalTrials.gg
CompletedNCT05468164Updated Sep 19, 2025Results posted

A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants

A Phase 1 interventional study of Selpercatinib and Omeprazole in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 4 years 1 month after the study started (first participant enrolled May 2018, registered Jul 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to assess the effect of food on how fast selpercatinib gets into the bloodstream and how long it takes the body to remove it after a high-fat meal, and the effect of a change in gastric pH after multiple doses of omeprazole on how fast selpercatinib gets into the bloodstream and how long it takes the body to remove it when administered under fasted and fed conditions in healthy participants. The study will also evaluate the safety and tolerability of selpercatinib in healthy participants. The study will last up to 33 days excluding the screening period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-vasectomized, male participants must have agreed to use a condom with spermicide or abstain from sexual intercourse during the study until 6 months after the last dosing. (No restrictions were required for a vasectomized male provided his vasectomy had been performed 4 months or more prior to the first dosing of study drug)
  • If male, must have agreed not to donate sperm from the first dosing until 6 months after the last dosing
  • Female participants of non- who are agreeable to take measures until study completion
  • (BMI) ≥ 18.0 and ≤ 32.0 kilograms per meter squared (kg/m²) and had a minimum weight of at least 50 kg at screening
  • Have normal blood pressure, pulse rate, (ECG), and blood and urine laboratory test results that are acceptable for the study

Exclusion criteria

Exclusion Criteria:

  • Had a history of gastritis, gastrointestinal tract or hepatic disorder or other clinical condition that might have, in the opinion of the Principal Investigator or designee, and as confirmed by the Sponsor, affected the absorption, distribution, biotransformation, or excretion of LOXO 292 or omeprazole
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1: ABCD

    Participants received: * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 1 in fasted state. * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 2 in fed state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 3 in fasted state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 4 in fed state. Periods 1 and 2, 2 and 3 were separated by a 7-day washout period. There was no washout between Periods 3 and 4.

    Drug: Selpercatinib · Drug: Omeprazole

  • Experimental
    Treatment Sequence 2: ABDC

    Participants received: * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 1 in fasted state. * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 2 in fed state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 3 in fed state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 4 in fasted state. Periods 1 and 2, 2 and 3 were separated by a 7-day washout period. There was no washout between Periods 3 and 4.

    Drug: Selpercatinib · Drug: Omeprazole

  • Experimental
    Treatment Sequence 3: BACD

    Participants received: * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 1 in fed state. * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 2 in fasted state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 3 in fasted state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 4 in fed state. Periods 1 and 2, 2 and 3 were separated by a 7-day washout period. There was no washout between Periods 3 and 4.

    Drug: Selpercatinib · Drug: Omeprazole

  • Experimental
    Treatment Sequence 4: BADC

    Participants received: * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 1 in fed state. * Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 2 in fasted state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 3 in fed state. * Multiple daily oral doses of 40 mg omeprazole administered on Day 1 to Day 7 along with single oral dose of 160 mg selpercatinib on Day 1 of Period 4 in fasted state. Periods 1 and 2, 2 and 3 were separated by a 7-day washout period. There was no washout between Periods 3 and 4.

    Drug: Selpercatinib · Drug: Omeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib

    PK: AUC0-t of Selpercatinib was reported.

    Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.

  2. PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib

    PK: AUC0-inf of Selpercatinib was reported.

    Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.

  3. PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib

    PK: AUC%extrap of Selpercatinib was reported.

    Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.

  4. PK: Maximum Observed Concentration (Cmax) of Selpercatinib

    PK: Cmax of Selpercatinib was reported.

    Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.

  5. PK: Time to Reach Cmax (Tmax) of Selpercatinib

    PK: Tmax of Selpercatinib was reported.

    Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.

  6. PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib

    PK: Kel of Selpercatinib was reported.

    Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.

  7. PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib

    PK: CL/F of Selpercatinib was reported.

    Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.

  8. PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib

    PK: t½ of Selpercatinib was reported.

    Time frame: Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.

07

Results

Posted Sep 19, 2025

Participant flow

A total of 20 participants were enrolled in this study. Participants were randomly assigned to 1 of 4 treatment sequences (ABCD, ABDC, BACD, and BADC). Treatment A was a single oral dose of 160 milligrams (mg) selpercatinib under fasting condition, Treatment B was a single oral dose of 160 mg selpercatinib under fed condition, (contd.)

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneTreatment Sequence 1: ABCDTreatment Sequence 2: ABDCTreatment Sequence 3: BACDTreatment Sequence 3: BADC
Started5555
Received at least 1 dose of study drug5555
Completed5555
Not completed0000
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneTreatment Sequence 1: ABCDTreatment Sequence 2: ABDCTreatment Sequence 3: BACDTreatment Sequence 3: BADC
Started5555
Received at least 1 dose of study drug5555
Completed5555
Not completed0000
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneTreatment Sequence 1: ABCDTreatment Sequence 2: ABDCTreatment Sequence 3: BACDTreatment Sequence 3: BADC
Started5555
Received at least 1 dose of study drug5555
Completed5555
Not completed0000
Treatment Period 4
Participant flow — Treatment Period 4
MilestoneTreatment Sequence 1: ABCDTreatment Sequence 2: ABDCTreatment Sequence 3: BACDTreatment Sequence 3: BADC
Started5555
Received at least 1 dose of study drug5554
Completed5554
Not completed0001
Withdrew: Adverse event0001

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib

PK: AUC0-t of Selpercatinib was reported.

Time frame:
Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
nanogram*hour per milliliter (ng*h/mL)Treatment A: 160 mg Selpercatinib (Fasted)Treatment B: 160 mg Selpercatinib (Fed)Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted)Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed)
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib26160 ± 38.928400 ± 20.47973 ± 161.926570 ± 14.1
PrimaryPK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib

PK: AUC0-inf of Selpercatinib was reported.

Time frame:
Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
Reported as:
Geometric mean · ng*h/mL
PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib
ng*h/mLTreatment A: 160 mg Selpercatinib (Fasted)Treatment B: 160 mg Selpercatinib (Fed)Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted)Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed)
PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib26280 ± 38.928530 ± 20.48256 ± 143.326770 ± 13.8
PrimaryPK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib

PK: AUC%extrap of Selpercatinib was reported.

Time frame:
Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
Reported as:
Mean · percentage of AUC0-inf extrapolated
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib
percentage of AUC0-inf extrapolatedTreatment A: 160 mg Selpercatinib (Fasted)Treatment B: 160 mg Selpercatinib (Fed)Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted)Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed)
PK: Percent of AUC0-inf Extrapolated (AUC%Extrap) of Selpercatinib0.4468 ± 0.149090.4541 ± 0.220003.065 ± 7.58410.7158 ± 0.46382
PrimaryPK: Maximum Observed Concentration (Cmax) of Selpercatinib

PK: Cmax of Selpercatinib was reported.

Time frame:
Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of Selpercatinib
nanograms per milliliter (ng/mL)Treatment A: 160 mg Selpercatinib (Fasted)Treatment B: 160 mg Selpercatinib (Fed)Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted)Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed)
PK: Maximum Observed Concentration (Cmax) of Selpercatinib2024 ± 60.41745 ± 20.9251.5 ± 263.91023 ± 24.7
PrimaryPK: Time to Reach Cmax (Tmax) of Selpercatinib

PK: Tmax of Selpercatinib was reported.

Time frame:
Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
Reported as:
Median · hours (h)
PK: Time to Reach Cmax (Tmax) of Selpercatinib
hours (h)Treatment A: 160 mg Selpercatinib (Fasted)Treatment B: 160 mg Selpercatinib (Fed)Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted)Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed)
PK: Time to Reach Cmax (Tmax) of Selpercatinib1.502 (1.00 to 24.00)3.997 (2.01 to 6.00)2.501 (1.50 to 23.97)6.011 (3.00 to 23.93)
PrimaryPK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib

PK: Kel of Selpercatinib was reported.

Time frame:
Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
Reported as:
Mean · 1/hour
PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib
1/hourTreatment A: 160 mg Selpercatinib (Fasted)Treatment B: 160 mg Selpercatinib (Fed)Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted)Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed)
PK: Apparent First Order Terminal Elimination Rate Constant (Kel) of Selpercatinib0.02445 ± 0.00587550.02282 ± 0.00474760.02207 ± 0.00959090.02214 ± 0.0077557
PrimaryPK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib

PK: CL/F of Selpercatinib was reported.

Time frame:
Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
Reported as:
Mean · Liters/hour
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib
Liters/hourTreatment A: 160 mg Selpercatinib (Fasted)Treatment B: 160 mg Selpercatinib (Fed)Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted)Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed)
PK: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of Selpercatinib6.585 ± 3.23925.717 ± 1.156050.45 ± 135.826.031 ± 0.81650
PrimaryPK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib

PK: t½ of Selpercatinib was reported.

Time frame:
Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168 hours post dose in Periods 1, 2, 3, and 4.
Reported as:
Mean · h
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib
hTreatment A: 160 mg Selpercatinib (Fasted)Treatment B: 160 mg Selpercatinib (Fed)Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted)Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed)
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib29.801 ± 6.615531.641 ± 6.527337.288 ± 16.016735.841 ± 14.7170

Adverse events

Collected over Baseline to End of Follow-up (Up To 39 Days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: 160 mg Selpercatinib (Fasted)0/20 (0%)0/20 (0%)3/20 (15%)
Treatment B: 160 mg Selpercatinib (Fed)0/20 (0%)0/20 (0%)6/20 (30%)
Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted)0/19 (0%)0/19 (0%)7/19 (36.8%)
Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed)0/20 (0%)0/20 (0%)8/20 (40%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventTreatment A: 160 mg Selpercatinib (Fasted)Treatment B: 160 mg Selpercatinib (Fed)Treatment C: 160 mg Selpercatinib + 40 mg Omeprazole (Fasted)Treatment D: 160 mg Selpercatinib + 40 mg Omeprazole (Fed)
HeadacheNervous system disorders0/200/203/192/20
Abdominal discomfortGastrointestinal disorders0/200/200/192/20
DyspepsiaGastrointestinal disorders0/202/200/191/20
FlatulenceGastrointestinal disorders0/200/200/192/20
Abdominal pain lowerGastrointestinal disorders0/200/201/190/20
Abdominal pain upperGastrointestinal disorders0/200/201/190/20
Alanine aminotransferase increasedInvestigations0/200/201/191/20
Blood creatine phosphokinase increasedInvestigations0/200/201/190/20
Weight decreasedInvestigations0/200/201/191/20
HypertriglyceridaemiaMetabolism and nutrition disorders1/200/201/191/20

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Treatment Sequence 1: ABCDTreatment Sequence 2: ABDCTreatment Sequence 3: BACDTreatment Sequence 3: BADCTotal
Mean45.0 ± 6.8238.2 ± 6.5041.8 ± 10.3538.4 ± 7.4440.9 ± 7.82
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1: ABCDTreatment Sequence 2: ABDCTreatment Sequence 3: BACDTreatment Sequence 3: BADCTotal
Female322310
Male233210
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence 1: ABCDTreatment Sequence 2: ABDCTreatment Sequence 3: BACDTreatment Sequence 3: BADCTotal
Hispanic or Latino545519
Not Hispanic or Latino01001
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence 1: ABCDTreatment Sequence 2: ABDCTreatment Sequence 3: BACDTreatment Sequence 3: BADCTotal
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White545519
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Treatment Sequence 1: ABCDTreatment Sequence 2: ABDCTreatment Sequence 3: BACDTreatment Sequence 3: BADCTotal
United States555520
08

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Sep 2018, 3 months.

Results were first posted in Sep 2025, 7 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2022
First posted
Jul 21, 2022
StartActual
May 31, 2018
Primary completionActual
Sep 13, 2018
CompletionActual
Sep 13, 2018
Results first posted
Sep 19, 2025
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05468164
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Jul 21, 2022
Start date
May 31, 2018
Primary completion
Sep 13, 2018
Completion
Sep 13, 2018
Results posted
Sep 19, 2025
Last update
Sep 19, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion